AEs reported in greater than or equal to 5 percent of patisiran patients and seen at least 3 percent more frequently with patisiran compared with placebo were infusionrelated reactions 122 percent vs 9 percent respectively arthralgia 77 percent vs 45 percent respectively and muscle spasms 66 percent vs 22 percent respectively